Paolo Tarantino, MD

Excellent review article by @ptarantinomd.bsky.social on redefining Her-2 testing @ethicsdoctorp.bsky.social @acochran12733.bsky.social ascopubs.org/doi/10.1200/... @oncoalert.bsky.social

✨EXCLUSIVE PREVIEW: Ahead of the 2025 @ascocancer.bsky.social Annual Meeting, breast cancer experts highlight this year's most anticipated abstracts @stolaney1.bsky.social @ptarantinomd.bsky.social #ASCO25 #bcsm www.onclive.com/view/breast-...

Glad to have had Giacomo De Micheli at Dana-Farber’s Breast Oncology Center - Paolo Tarantino @ptarantinomd.bsky.social @stolaney1.bsky.social @dfcibreastonc.bsky.social oncodaily.com/blog/paolo-t... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Paolo Tarantino Highlights ESMO Breast 25 as ESMO Ambassador @ptarantinomd.bsky.social @myesmo.bsky.social oncodaily.com/blog/paolo-t... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOBreast25 #ESMO

#ESMOBreast25: Do not miss the latest research findings in #BreastCancer brought to you by the #ESMOAmbassadors & become part of the conversation. #bcsm 🔗 ow.ly/VtAE50VP4Jf

Congratulations to Drs. Paolo Tarantino, Caterina Sposetti, Pietro De Placido, and Tess O'Meara on receiving the prestigious #ConquerCancer #ASCO Merit Awards! @ptarantinomd.bsky.social @csposettimd.bsky.social

Don't miss "The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development," a Cancer Discovery review by #AACR25 speakers Elisabeth de Vries and @raffcolo.bsky.social (along with Pat LoRusso & @ptarantinomd.bsky.social) doi.org/10.1158/2159...

Paolo Tarantino: ADCs are rapidly moving to earlier line treatment for breast cancer @ptarantinomd.bsky.social oncodaily.com/blog/paolo-t... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ADCs #BreastCancer

Novel Adjuvant Strategies Reshape HER2+ Breast Cancer Treatment @ptarantinomd.bsky.social @danafarbernews.bsky.social #BreastCancer www.onclive.com/view/novel-a...

St. Gallen Consensus 2025 – 10 key votes - Paolo Tarantino @ptarantinomd.bsky.social oncodaily.com/blog/paolo-t... #Cancer #Medicine #Health #BreastCancer #CancerConference #Oncology #OncoDaily

Register for the @OncLive Breast Cancer State of the Science Summit at the Hilton Boston in Back Bay on March 26th, hosted by Dr. Paolo Tarantino @ptarantinomd.bsky.social. All are free to attend including doctors, nurses, pharmacists, clinical researchers, etc. 👉 event.onclive.com/QVZ54b?RefId...

A pleasure to join the gender balance session at JSMO25 - Paolo Tarantino @ptarantinomd.bsky.social oncodaily.com/blog/253704 #Cancer #CancerResearch #Medicine #Health #JSMO25 #Oncology #OncoDaily

2025 is anticipated to be the year with the highest number of phase 3 ADC trials read outs in breast oncology, with impact for all breast cancer subtypes. Here’s 8 ADC breast cancer trials expected to reshape practice in 2025:

Check out this new systematic review and meta-analysis discussing #AntibodyDrugConjugates in patients with advanced/metastatic HER2-low-expressing #BreastCancer. 🔓https://pubmed.ncbi.nlm.nih.gov/39574495/ @ptarantinomd.bsky.social

No standing ovations at #SABCS24, but maybe there should have been! 🎤 (Granted, I didn’t catch everything in the room.) For MBC, the #PATINA and #EMBER data bring meaningful progress for patients with ER+ & triple-positive breast cancer. Exciting strides being made.

Great discussion of novel biomarkers and HER2-targeted TKIs by @ptarantinomd.bsky.social @dfcibreastonc.bsky.social

📌“Optimizing outcomes for HER2-expressing breast cancer through novel biomarkers and TKIs” Great discussion by @ptarantinomd.bsky.social 👏🏻 #SABCS24 #day3 @oncoalert.bsky.social #OncoAlertAF @danafarber.bsky.social

‼️When you thought you had the #SABCS24 program figured out, here’s the PRACTICE-CHANGING #PATINA trial being added! For the impatient ones, press release here: www.businesswire.com/news/home/20... If you’re in San Anyonio, though, make sure to attend the data presentation today by Otto Metzger!

Dr. Paolo Tarantino (@ptarantinomd.bsky.social) will serve as a moderator in the #SABCS24 Educational Session 7. He will also give a presentation titled “Aiming for the Target: Increasing the Precision of #ADCs through Novel Biomarkers and Innovative Molecular Constructs”

📌Education Session: People's Choice -The Future in Antibody Drug Conjugates Topic 1: “The ABC of ADCs: History, Mechanism of Action, Mechanisms of Resistance” by John Lambert 👏🏻 Moderator Introduction by @ptarantinomd.bsky.social 👏🏻 #SABCS24 #day2 @oncoalert.bsky.social #OncoAlertAF

Dr. Paolo Tarantino (@ptarantinomd.bsky.social) will be the invited discussant for Session 8: “Novel HER2 Therapeutics” at #SABCS24, his discussion will focus on #RadiationOncology. 🗓️ Thursday, December 12th ⏰ 7:30 - 7:45 am CST (8:30 – 8:45 am EST) 📍 Stars at Night 1-2

Outstanding spotlight poster discussion by Thomas Grinda from Gustave Roussy. Promising results with the 1L combination of chemo, IO and VEGF blockade for mTNBC. Will the inclusion of IO in the combo change the story of VEGF, previously thought not to improve long-term outcomes for breast cancer?

#SABCS24 day 1 kicks off with an interesting @FDAOncology special session on drug approval. First talk tackles the approval of adjuvant ribociclib per NATALEE. Two post-marketing commitments: to provide efficacy in a broader diverse population, and to provide updates on OS. #bcsm

Upcoming SABCS24 session on the future of ADCs - Paolo Tarantino oncodaily.com/blog/201316 @ptarantinomd.bsky.social #Cancer #OncoDaily #Oncology #SABCS2024 #Medicine #Health

Awesome #SABCS24 starter pack! 👇

Small preview from Wednesday’s #SABCS24 session on the future of ADCs Question: what do all these ongoing phase 3 ADC trials have in common? 🗓️ Dec 11, 3.30 pm, Hemisfair Ballroom 1-2

#SABCS24 here we go!!

The @dfcibreastonc.bsky.social team is on its way— see you all soon in San Antonio! #SABCS24

Check out this recent review on the role of #AntibodyDrugConjugates in the treatment of patients with #BreastCancerBrainMetastases. pubmed.ncbi.nlm.nih.gov/39529890/ #StaceyPan @drsarahsammons.bsky.social @nlinmd.bsky.social @stolaney1.bsky.social @ilanaschlam.bsky.social @ptarantinomd.bsky.social

Make sure to follow @dfcibreastonc.bsky.social for updates on the latest research efforts by DFCI BOC and for periodic research digest with recent news in breast oncology! @stolaney1.bsky.social

Elacestrant as second-line therapy for ESR1m, endocrine-sensitive disease: A discussion with @oncbrothers.bsky.social and @ptarantinomd.bsky.social. #BCSM www.targetedonc.com/view/elacest...

Impressive report in @NEJM. In a cohort of pregnant women with unusual clinical cfDNA-sequencing results, 52/107 were found to have an incidental cancer via whole-body MRI, with a sensitivity of 98.0% and specificity of 88.5%. Physical exam & labs were of limited use. www.nejm.org/doi/full/10....

Twitter, as we knew it, is gone, stained by new horrific algorithms that promote misinformation. 🦋 is a much better place for those interested in science. And it’s growing fast. Thanks @jamiedoggett for highlighting our efforts to rebuild a safe place for scientific discussion.

Prima lo si immaginava, ora la conferma arriva dai più importanti giornali del 🌍: su @bsky.app le visualizzazioni e interazioni sono significativamente più elevate rispetto a Threads, con nessun algoritmo manipolato come su X. Ci avviciniamo a una nuova era dei social! ☕ bsky.social/about/blog/1...

Good to see our protocol paper for DECIPHER in press at ESMO GO! ctDNA 🧬 after surgery will detect pts with HER2➕ gastroesophageal #cancer at high risk of recurring 🧬➕ receive TDxD instead of usual post-op chemo Hope to #cure some micrometastatic cancers 🙏 www.sciencedirect.com/science/arti...

10 days to #SABCS24. Excited to present at the conference the results of 4 studies, made possible by collaborations with brilliant Dana-Farber colleagues and with multiple external partners (RevealGenomics, Yale, Novartis). Come meet me at the posters on December 11th and 12th!

Is carbo needed for the neoadjuvant treatment of HER2+ BC? The #HELEN006 ph 3 trial randomized pts to TCHPx6 vs nabTHPx6. nabTHP had significantly higher pCR rate vs TCHP (66% vs 57%), with less toxicities. CompassHER-pCR trial ongoing to validate THP (x4) www.sciencedirect.com/science/arti...

The results of SONIA are out on @Nature. 1L use of palbo did not improve PFS over 2L use, but led to more AEs & costs. An evolving treatment landscape challenges its interpretation— yet it shows that sequencing trials are possible. Congrats to the authors! www.nature.com/articles/s41...

OS results of KN-522 out in @NEJM. Terrific news: adding pembro to neoadjuvant chemo for TNBC saves lives (5% 5-year Δ). Bad news: we’re stuck with giving 5 drugs to all patients with stage II-III TNBC, with permanent toxicity for many. Biomarkers, please! t.co/8S9YWOP1lr

Sacituzumab tirumotecan (aka sac-TMT aka SKB264/MK-2870) approved in China for patients with advanced or metastatic triple negative breast cancer (TNBC) who have received at least 2 prior therapies. This brings the total number of approved ADCs to 13 worldwide (of which 11 by US FDA)!

ADC trivia: what’s the linker stability of the newly approved (by Chinese NMPA) sacituzumab tirumotecan? 1, 2, 3, 4, 5, 6, 7, or 8? For more info on ADC linker (in)stabilities: aacrjournals.org/cancerdiscov...

Thank you @ptarantinomd.bsky.social for the excellent list of @sabcs.bsky.social presentations!

⭐️Nice review @theaacr.bsky.social journal Cancer Discovery 👉🏼The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development @ptarantinomd.bsky.social bit.ly/3YZn7OK

Regular abstracts from #SABCS24 are out! 3407 pages of new breast cancer discoveries. Find them here: sabcs.org/Portals/0/Do...

Paging #MedSky Oncs: #OncSky will really hit the next level if/when Vogl from New York gets onto #Bluesky. (For those who don’t know, he is a legend of #oncology who is no holds barred at a conference Q&A mic). We need his voice and inquisitive perspective - how about we aim to get him on by #GI25

Does anyone have the 🦋 version of this list?? @tmprowell.bsky.social @erikahamilton9.bsky.social @drsgraff.bsky.social @maryamlustberg.bsky.social @drteplinsky.bsky.social @ptarantinomd.bsky.social

Honoured to be quoted by @ptarantinomd.bsky.social on his abstract selection #SABCS24 Preplanned interim analysis from EUROPA phase 3 trial #breastcancer #medonc #radonc #OncoAlert @oncoalert.bsky.social #Bluesky #exodus #Science